Interest has been growing in the development of medical radioisotopes used for noninvasive nuclear medicine imaging of disease and cancer therapy. Especially the development of an alternative production scheme of ⁹⁹Mo, the mother radioisotope of ^99mTc used for imaging, is required, because the current supply chain of the reactor product ⁹⁹Mo is fragile worldwide. We have proposed a new production scheme of ⁹⁹Mo as well as therapeutic radioisotopes, such as ⁶⁴Cu and ⁶⁷Cu, using accelerator neutrons provided by the ^natC(d,n) reaction. Based on this scheme we have obtained high-quality ^99mTc, ⁶⁴Cu, and ⁶⁷Cu suitable for clinical use by developing both production and separation methods of the radioisotopes. We proposed a new facility to constantly and reliably produce a wide variety of high-quality, carrier-free radioisotopes, including ⁹⁹Mo, with accelerator neutrons. We report on the development of the proposed scheme and future prospects of the facility toward the domestic production of medical radioisotopes.

用于疾病和癌症治疗的无创核医学成像的医用放射性同位素的开发越来越受到关注。尤其需要开发⁹⁹ Mo（用于成像的^99m Tc的母放射性同位素）的替代生产方案，因为目前反应堆产品⁹⁹ Mo 的供应链在全球范围内都很脆弱。我们提出了一种新的⁹⁹ Mo 以及治疗性放射性同位素（例如⁶⁴ Cu 和⁶⁷ Cu）的生产方案，使用由^nat C( d , n ) 反应提供的加速器中子。基于这个方案我们获得了高质量的^99m通过开发放射性同位素的生产和分离方法，使Tc、⁶⁴ Cu 和⁶⁷ Cu 适用于临床。我们提议建立一个新设施，以持续可靠地生产各种具有加速器中子的高质量、无载流子放射性同位素，包括⁹⁹ Mo。我们报告了拟议计划的发展以及该设施在国内生产医用放射性同位素的前景。